Q1 2025 EPS Estimates for Zimmer Biomet Holdings, Inc. Decreased by Zacks Research (NYSE:ZBH)

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities researchers at Zacks Research reduced their Q1 2025 earnings estimates for shares of Zimmer Biomet in a research report issued on Wednesday, August 28th. Zacks Research analyst U. Biswas now expects that the medical equipment provider will post earnings per share of $2.02 for the quarter, down from their previous estimate of $2.06. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.06 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q2 2025 earnings at $2.13 EPS, Q4 2025 earnings at $2.30 EPS and Q1 2026 earnings at $2.29 EPS.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 EPS for the quarter, topping the consensus estimate of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The business had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.94 billion. During the same period last year, the business posted $1.82 earnings per share. Zimmer Biomet’s quarterly revenue was up 3.9% compared to the same quarter last year.

A number of other brokerages have also recently commented on ZBH. UBS Group dropped their target price on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a report on Thursday, August 8th. Raymond James lowered their target price on shares of Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Canaccord Genuity Group cut their price target on Zimmer Biomet from $130.00 to $120.00 and set a “hold” rating on the stock in a research note on Tuesday, August 20th. Robert W. Baird reduced their price objective on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Finally, Truist Financial dropped their target price on Zimmer Biomet from $130.00 to $117.00 and set a “hold” rating on the stock in a report on Tuesday, July 16th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $126.41.

Zimmer Biomet Trading Up 0.7 %

NYSE ZBH opened at $115.47 on Friday. The stock’s 50 day moving average is $109.61 and its 200 day moving average is $117.44. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $23.76 billion, a PE ratio of 24.99, a P/E/G ratio of 2.04 and a beta of 1.01. Zimmer Biomet has a twelve month low of $102.00 and a twelve month high of $133.90.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.83%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ZBH. Chicago Partners Investment Group LLC increased its stake in Zimmer Biomet by 3.3% during the fourth quarter. Chicago Partners Investment Group LLC now owns 2,894 shares of the medical equipment provider’s stock worth $349,000 after purchasing an additional 92 shares during the period. North Star Investment Management Corp. lifted its holdings in Zimmer Biomet by 16.6% during the 1st quarter. North Star Investment Management Corp. now owns 669 shares of the medical equipment provider’s stock worth $88,000 after buying an additional 95 shares in the last quarter. Ballentine Partners LLC boosted its position in Zimmer Biomet by 2.6% in the 1st quarter. Ballentine Partners LLC now owns 3,957 shares of the medical equipment provider’s stock valued at $522,000 after buying an additional 100 shares during the period. First Bancorp Inc ME grew its stake in shares of Zimmer Biomet by 5.3% in the first quarter. First Bancorp Inc ME now owns 1,970 shares of the medical equipment provider’s stock worth $260,000 after acquiring an additional 100 shares in the last quarter. Finally, Romano Brothers AND Company increased its position in shares of Zimmer Biomet by 1.1% during the first quarter. Romano Brothers AND Company now owns 9,514 shares of the medical equipment provider’s stock worth $1,256,000 after acquiring an additional 100 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.